Sheng‐Yu Ku
Harvard University(US)Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Prostate Cancer Treatment and Research, Epigenetics and DNA Methylation, Cancer, Lipids, and Metabolism, Renal and related cancers
Most-Cited Works
- → Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance(2017)1,074 cited
- → SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer(2017)1,023 cited
- → Towards precision oncology in advanced prostate cancer(2019)226 cited
- → Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer(2020)190 cited
- → Transcriptional mediators of treatment resistance in lethal prostate cancer(2021)188 cited
- → Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer(2021)162 cited
- → YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage(2015)123 cited
- → TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup(2017)109 cited
- → Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer(2023)107 cited
- → Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma(2018)93 cited